Brom-ergocryptine in the Treatment of Phenothiazine-Induced Galactorrhoea

Abstract

An ergot alkaloid, 2-br-alpha-ergocryptine (CB 154), referred to hereafter as brom-ergocryptine, has been reported to inhibit puerperal lactation (Varga, Lutterbeck et al., 1972), and to terminate breast secretion in patients with inappropriate lactation (Lutterbeck, Pryor et al., 1971). Besser, Park et al. (1972) found that the drug suppressed elevated levels of plasma prolactin in five patients whose inappropriate lactation was due to a variety of causes. This hormonal effect was accompanied by clinical changes such as the disappearance of galactorrhoea, return of menstruation, and an increase in sexual potency.